Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Myeloma PFS boosted by elotuzumab add-on therapy

Dimopoulos MA et al. EHA (European Hematology Association) Congress, Abstract LB2606.

Key clinical point: Elotuzumab may have synergistic clinical activity with pomalidomide against multiple myeloma.

Major finding: Median progression-free survival was 10.3 months with elotuzumab, pomalidomide, and dexamethasone vs. 4.7 months with pomalidomide and dexamethasone.

Study details: Randomized open-label phase 2 trial of 120 patients with multiple myeloma relapsed or refractory after 2 or more prior lines of therapy.

Disclosures: Bristol-Myers Squibb and AbbVie Biotherapeutics funded the study. Dr. Dimopoulos disclosed honoraria and/or consulting fees from Amgen, BMS, Celgene, Janssen and Takeda.

Source: Dimopoulos MA et al. EHA (European Hematology Association) Congress, Abstract LB2606.

Read the article.

Citation:

Dimopoulos MA et al. EHA (European Hematology Association) Congress, Abstract LB2606.

This Week's Must Reads

Corticosteroid use poses risk of febrile neutropenia, Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8

5F9 plus rituximab looks durable in NH, Advani R et al. N Engl J Med. 2018;379:1711-21

Systematic review examines sickle cell trait complications, Naik RP et al. Ann Intern Med. 2018 Oct 30. doi:10.7326/M18-1161

Cardiovascular risks in hemophilia A, Humphries TJ et al. Adv Med Sci. 2018;63(2):329-33

Study evaluates rapid bacterial testing of platelets, Booth AL et al. AABB18, Abstract INV4

Must Reads in Multiple Myeloma

Osteoporosis tied to mortality risk in women with multiple myeloma, Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):597-602.e1.

Improved myeloma outcomes associated with having prescription drug coverage, Olszewski A et al. J Clin Oncol. 2018 Aug 16. doi: 10.1200/JCO.2018.77.8894

Simulated model could target myeloma treatment, Ubels J et al. Nat Commun. 2018 Jul 27. doi: 10.1038/s41467-018-05348-5.

Researchers propose frailty index for older patients with multiple myeloma, Mian HS et al. JCO Clin Cancer Inform. 2018 Jul 25. doi: 10.1200/CCI.18.00043.

Myeloma PFS boosted by elotuzumab add-on therapy, Dimopoulos MA et al. EHA (European Hematology Association) Congress, Abstract LB2606.